Sign in
SuspendedPhase 2

IORT on Borderline Resectable Pancreatic Cancer

Key facts

Who runs it
Universita di Verona
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Suspended
Phase
Phase 2
People taking part
100 people, planned
Started
1 Oct 2019
Expected to end
30 Dec 2027
Type of study
Interventional
Treatments tested
  • Intraoperative radiotherapy
Record updated
7 May 2024
Why it stopped
Logistic and financial reasons

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • • Biopsy-proven, previously untreated borderline resectable PC, defined according to the NCCN guidelines v1.2019; Age 18-80 years; Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; Adequate bone marrow function (absolute neutrophil count ≥1500 per cubic millimeter; platelet count ≥100.000 per cubic millimeter; hemoglobin level ≥10 g per deciliter), liver function (serum total bilirubin level ≤1.5 times the upper limit of the normal range), and renal function (creatinine clearance ≥50 ml per minute); Ability to understand the characteristics of the clinical trial; Written informed consent

Who cannot take part

  • • Ampullary, biliary, or duodenal adenocarcinoma; pancreatic adenocarcinoma in the background of an intraductal papillary mucinous neoplasia (IPMN), other uncommon pancreatic adenocarcinomas (acinar-cell, squamous, giant-cell osteoclastic-like); Invasive cancer in the last 5 years requiring radiation therapy to the upper abdomen or chemotherapy; Symptomatic heart failure or coronary artery disease; Pregnant or lactating women; Impaired mental state or language problems

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This phase II study investigates the efficacy of IORT for patients with borderline resectable pancreatic cancer. The purpose of the study is to investigate whether the addition of IORT, after FOLOFIRINOX-base chemotherapy, and SBRT, increases the 3-year survival rate. A total of 101 patients will be enrolled, and these patients will receive IORT of 10 to 20 Gy, according to the resection status (to the tumor bed after resection, or to the tumor in situ in case of non-resection).

The group in the trial

  • IORT groupTreatment being tested

    Intraoperative administration of 10 to 20 Gy after surgery or as an "in situ" treatment in case resection will not be performed

    Treatment: Intraoperative radiotherapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Study of Primary Chemotherapy, Stereotactic Body Radiation Therapy, and Intraoperative Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Publications
Record updated
7 May 2024